Publication | Closed Access
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
22
Citations
11
References
2018
Year
Relevent TrialPhase Ii TrialMedicineClinical TrialsPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyHealth Sciences
| Year | Citations | |
|---|---|---|
Page 1
Page 1